Jazeta (Sitagliptin Hydrochloride)

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This prevents the breakdown of the incretin hormones GLP‑1 and GIP, which increases insulin secretion only when glucose is elevated and suppresses glucagon release, thereby lowering blood glucose levels.

The dosage of Jazeta is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. The prescriber sets the appropriate strength and dosing schedule according to current treatment guidelines.

Safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Jazeta product page at gnhindia.com, providing the required quantity and your institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, then replies with pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower intrinsic risk of hypoglycaemia because it enhances insulin secretion only when glucose levels are elevated. Unlike insulin, it is administered orally and does not require injection, offering a convenient option for many patients.

Jazeta should be stored at ambient temperature, below 25 °C, in its original blister pack or bottle. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability throughout its shelf‑life.

Jazeta is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious adverse events reported include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Jazeta is contraindicated in patients with a known hypersensitivity to sitagliptin or any of the tablet’s excipients, and it should be avoided in individuals with a history of pancreatitis. Caution is also advised for patients with severe renal impairment where dose adjustment may be required.